[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583246":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":16,"locations":7,"responsibleParty":22,"collaborators":7,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":30,"eligibilityCriteria":31,"healthyVolunteers":26,"sex":32,"minAge":33,"maxAge":7,"enrollmentInfo":34,"targetDuration":7,"studyType":37,"phases":38,"briefSummary":40,"conditions":41,"keywords":7,"overallStatus":43,"whyStopped":7,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":7},{"fullName":5,"class":6},"Yonsei University","OTHER",null,[9,13],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","ATP-C135","A wearable long-term electrocardiogram monitoring device that monitors electrocardiograms by attaching it for up to 14 days.",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"ATP-C75","A wearable long-term electrocardiogram monitoring device that monitors electrocardiograms by attaching it for up to 7 days.",[17],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Ik-Seong Cho, MD,PhD","CONTACT","82-10-8975-2413","IKSUNGCHO@yuhs.ac",{"type":23,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100583246","phase-3-evaluation-of-the-efficacy-and-safety-of-wearable-ecg-at-patch-in-patients-with-hypertrophic-cardiomyopathy-requiring-48-hour-holter-monitoringevaluation-of-the-efficacy-and-safety-of-wearable-ecg-at-patch-in-patients-with-hypertrophic-cardiomyopathy-requiring-48-hour-holter-monitoring-100583246",false,"NCT06873828","Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring","Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring : A Prospective Superiority Study","ATP-HCM","Inclusion Criteria:\n\n1. Male and female subjects aged 19 years or older\n2. Subjects diagnosed with hypertrophic cardiomyopathy who require 48-hour Holter examination\n\nExclusion Criteria:\n\n1. Those judged by the investigator to be unsuitable for this clinical trial or those who may increase the risk due to participation in the clinical trial\n2. Those with sensitive or allergic skin, skin diseases such as skin cancer or rashes\n3. Those with pacemakers, implantable cardioverter-defibrillators, or other implantable electrical devices\n4. Pregnant women","ALL","19 Years",{"count":35,"type":36},100,"ESTIMATED","INTERVENTIONAL",[39],"PHASE3","* Validation of validity, superiority, and safety of data analysis results using AT-Patch compared to 48-hour Holter test results\n* Number of subjects: 100 (including 10% dropout rate)\n* Performance and safety were verified by simultaneously attaching a 48-hour Holter and a wearable Holter device (ATP-C75 or ATP-C135).",[42],"Hypertrophic Cardiomyopathy","NOT_YET_RECRUITING","2025-03-06",{"date":46,"type":47},"2025-03-13","ACTUAL",{"date":49,"type":36},"2025-03",{"date":51,"type":36},"2025-10",{"name":5,"class":6}]